Metsera says Novo Nordisk's new bid for obesity drugmaker is ‘superior' to revised Pfizer offer
1. Novo Nordisk's bid for Metsera values it at $86.20 per share. 2. Pfizer's offer for Metsera values it at $70 per share. 3. Metsera could reject Pfizer's bid if Novo's is deemed superior. 4. A lawsuit against Novo Nordisk alleges anti-competitive behavior by Pfizer. 5. Market for obesity and diabetes drugs affects both companies' strategies.